Media Center

Archives: Press Release

Entasis Therapeutics to Present Data at IDWeek on ETX2514SUL, a Novel Drug Targeting Multidrug-Resistant Acinetobacter baumannii Infections

Data also to be Presented on EXT0914, a Novel Drug Targeting Gonorrhea WALTHAM, Mass. — October 28, 2016 — Entasis Therapeutics, a leader in the discovery and development of breakthrough anti-infective products, today announced that it will present four posters at IDWeek 2016™, which is being held from October 26 – 30 in New Orleans. […]

Entasis Announces Initiation of Phase I Clinical Trial of ETX2514

ETX2514 in Combination with Sulbactam is Being Developed for the Treatment of Serious Drug-Resistant Hospital Infections WALTHAM, Mass. — October 26, 2016 — Entasis Therapeutics, a company focused on the discovery and development of breakthrough anti-infective products, today announced initiation of a Phase 1 clinical study of ETX2514. The study will evaluate the safety, tolerability […]

Entasis Announces Positive Phase 2 Data of ETX0914 for the Treatment of Gonorrhea

Validates Company’s Pathogen-targeted Discovery and Development Platform WALTHAM, Mass. — September 21, 2016 — Entasis Therapeutics, a company focused on the discovery and development of breakthrough anti-infective products, today announced that data from a Phase 2 study of ETX0914, the Company’s novel oral antibiotic compound, will be presented at the 2016 STD Prevention Conference in […]

Entasis Presents Data Supporting the Potential Clinical Utility of ETX2514, a Next-generation Beta-lactamase Inhibitor, at ASM Microbe 2016

New Drug Combination Demonstrates Activity Against Acinetobacter baumannii, a Multi-drug Resistant Pathogen and a Global Health Threat                WALTHAM, Mass. — June 28, 2016 — Entasis Therapeutics, a company focused on the discovery and development of breakthrough anti-infective products, today announced that preclinical data on ETX2514, a next-generation beta-lactamase inhibitor […]

Entasis to Present Preclinical Data on ETX2514, a Next-Generation Beta-lactamase Inhibitor, at ASM Microbe 2016

WALTHAM, Mass. — June 15, 2016 — Entasis Therapeutics, a company focused on the discovery and development of breakthrough anti-infective products, today announced that preclinical data from ETX2514, a next-generation beta-lactamase inhibitor, will be presented at the first annual American Society for Microbiology (ASM) Microbe 2016 conference taking place June 16 through 20, 2016 in […]

Entasis Announces $50 Million Series B Financing led by Clarus

Proceeds will Advance Pipeline of Innovative Anti-infective Products WALTHAM, Mass. — April 4, 2016 — Entasis Therapeutics, a company focused on the discovery and development of breakthrough anti-infective products, today announced the completion of a $50 million Series B financing to advance its pipeline of clinical and preclinical products. The financing was led by Clarus […]

Entasis Announces Appointments to its Scientific and Clinical Advisory Board

WALTHAM, Mass. — December 15, 2015 — Entasis Therapeutics, a company leveraging its expertise and a unique pathogen-targeted approach to develop and advance novel antibacterials, today announced the formation of the company’s Scientific and Clinical Advisory Board, comprised of experts in infectious diseases. The Advisory Board will provide strategic guidance on Entasis’ pipeline of preclinical […]

Entasis Appoints Robin David Isaacs as Chief Medical Officer

WALTHAM, Mass. – July 15, 2015 –  Entasis Therapeutics, a company leveraging its expertise and a unique pathogen-targeted approach to develop and advance novel antibacterials, today announced the appointment of Robin David Isaacs, M.D., as Chief Medical Officer. Dr. Isaacs has extensive experience as a pharmaceutical executive in the development and launch of vaccine and […]

Entasis Debuts with a Portfolio of Drug Candidates to Treat Serious Drug-resistant Bacterial Infections

Entasis Rounds Out Management Team with Michael E. Fitzgerald Chief Financial Officer and Chris White Chief Business Officer   WALTHAM, Mass. — July 1, 2015 — Entasis Therapeutics, a company leveraging its expertise and a unique pathogen-targeted approach to develop and advance novel antibacterials, debuted today with a portfolio of diverse, innovative investigational drugs for […]

AstraZeneca to create stand-alone company for small molecule early stage antibiotic R&D

Read the press release on AstraZeneca’s website.